UCB SA (UCBJF)
USD 150.7
(-5.46%)
USD 150.7
(-5.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.03 Billion EUR | 4.76% |
| 2022 | 2.9 Billion EUR | 36.6% |
| 2021 | 2.12 Billion EUR | -22.72% |
| 2020 | 2.74 Billion EUR | 114.44% |
| 2019 | 1.28 Billion EUR | -14.54% |
| 2018 | 1.49 Billion EUR | -4.7% |
| 2017 | 1.57 Billion EUR | -1.75% |
| 2016 | 1.6 Billion EUR | -27.49% |
| 2015 | 2.2 Billion EUR | 4.15% |
| 2014 | 2.12 Billion EUR | -22.91% |
| 2013 | 2.75 Billion EUR | 31.77% |
| 2012 | 2.08 Billion EUR | 14.86% |
| 2011 | 1.81 Billion EUR | -12.05% |
| 2010 | 2.06 Billion EUR | -7.89% |
| 2009 | 2.24 Billion EUR | -23.0% |
| 2008 | 2.91 Billion EUR | 20.37% |
| 2007 | 2.42 Billion EUR | -22.29% |
| 2006 | 3.11 Billion EUR | 195.17% |
| 2005 | 1.05 Billion EUR | -52.43% |
| 2004 | 2.21 Billion EUR | 446.05% |
| 2003 | 406.13 Million EUR | 62.67% |
| 2002 | 249.67 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.84 Billion EUR | 1.84% |
| 2024 Q1 | 2.98 Billion EUR | -1.81% |
| 2023 Q2 | 2.89 Billion EUR | 1.69% |
| 2023 FY | 3.03 Billion EUR | 4.76% |
| 2023 Q3 | 2.99 Billion EUR | 3.42% |
| 2023 Q4 | 3.03 Billion EUR | 1.44% |
| 2023 Q1 | 2.84 Billion EUR | -1.79% |
| 2022 Q2 | 3.01 Billion EUR | 1.58% |
| 2022 Q4 | 2.9 Billion EUR | 1.4% |
| 2022 FY | 2.9 Billion EUR | 36.6% |
| 2022 Q1 | 2.97 Billion EUR | 39.9% |
| 2022 Q3 | 2.86 Billion EUR | -5.2% |
| 2021 Q1 | 2.04 Billion EUR | -25.48% |
| 2021 Q2 | 2.08 Billion EUR | 1.71% |
| 2021 Q4 | 2.12 Billion EUR | 1.72% |
| 2021 Q3 | 2.08 Billion EUR | 0.24% |
| 2021 FY | 2.12 Billion EUR | -22.72% |
| 2020 Q4 | 2.74 Billion EUR | 1.29% |
| 2020 Q1 | 2.84 Billion EUR | 122.33% |
| 2020 Q3 | 2.71 Billion EUR | -5.93% |
| 2020 FY | 2.74 Billion EUR | 114.44% |
| 2020 Q2 | 2.88 Billion EUR | 1.23% |
| 2019 Q3 | 1.24 Billion EUR | -10.45% |
| 2019 FY | 1.28 Billion EUR | -14.54% |
| 2019 Q1 | 1.34 Billion EUR | -10.01% |
| 2019 Q2 | 1.38 Billion EUR | 2.89% |
| 2019 Q4 | 1.28 Billion EUR | 3.06% |
| 2018 Q3 | 1.46 Billion EUR | -12.41% |
| 2018 Q1 | 1.63 Billion EUR | 3.81% |
| 2018 FY | 1.49 Billion EUR | -4.7% |
| 2018 Q4 | 1.49 Billion EUR | 2.6% |
| 2018 Q2 | 1.66 Billion EUR | 2.14% |
| 2017 Q2 | 1.57 Billion EUR | 0.13% |
| 2017 Q3 | 1.57 Billion EUR | -0.38% |
| 2017 Q4 | 1.57 Billion EUR | 0.13% |
| 2017 FY | 1.57 Billion EUR | -1.75% |
| 2017 Q1 | 1.57 Billion EUR | -1.62% |
| 2016 Q1 | 2.15 Billion EUR | -2.22% |
| 2016 FY | 1.6 Billion EUR | -27.49% |
| 2016 Q4 | 1.6 Billion EUR | -4.07% |
| 2016 Q3 | 1.66 Billion EUR | -22.77% |
| 2016 Q2 | 2.16 Billion EUR | 0.09% |
| 2015 Q1 | 2.33 Billion EUR | 10.05% |
| 2015 Q3 | 2.38 Billion EUR | 2.19% |
| 2015 FY | 2.2 Billion EUR | 4.15% |
| 2015 Q4 | 2.2 Billion EUR | -7.38% |
| 2015 Q2 | 2.33 Billion EUR | 0.0% |
| 2014 Q2 | 2.36 Billion EUR | 0.08% |
| 2014 Q1 | 2.36 Billion EUR | -13.96% |
| 2014 FY | 2.12 Billion EUR | -22.91% |
| 2014 Q4 | 2.12 Billion EUR | 0.19% |
| 2014 Q3 | 2.11 Billion EUR | -10.64% |
| 2013 Q2 | 2.46 Billion EUR | 0.0% |
| 2013 Q1 | 2.46 Billion EUR | 18.16% |
| 2013 Q4 | 2.75 Billion EUR | 0.11% |
| 2013 FY | 2.75 Billion EUR | 31.77% |
| 2013 Q3 | 2.74 Billion EUR | 11.39% |
| 2012 FY | 2.08 Billion EUR | 14.86% |
| 2012 Q2 | 2.07 Billion EUR | 0.0% |
| 2012 Q4 | 2.08 Billion EUR | 0.0% |
| 2011 Q4 | 1.81 Billion EUR | 0.0% |
| 2011 Q2 | 1.76 Billion EUR | 0.0% |
| 2011 FY | 1.81 Billion EUR | -12.05% |
| 2010 Q4 | 2.06 Billion EUR | 0.0% |
| 2010 FY | 2.06 Billion EUR | -7.89% |
| 2010 Q2 | 2.76 Billion EUR | 0.0% |
| 2009 Q4 | 2.24 Billion EUR | 0.0% |
| 2009 FY | 2.24 Billion EUR | -23.0% |
| 2008 FY | 2.91 Billion EUR | 20.37% |
| 2007 FY | 2.42 Billion EUR | -22.29% |
| 2006 FY | 3.11 Billion EUR | 195.17% |
| 2005 FY | 1.05 Billion EUR | -52.43% |
| 2004 FY | 2.21 Billion EUR | 446.05% |
| 2003 FY | 406.13 Million EUR | 62.67% |
| 2002 FY | 249.67 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Qrons Inc. | 351.84 Thousand USD | -863343.485% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -6568.13% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -14844.904% |
| Adynxx, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -10105.885% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -64381.662% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -6904.358% |
| Skye Bioscience, Inc. | 4.61 Million USD | -65725.025% |
| Rebus Holdings, Inc. | 310 Thousand USD | -979900.0% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -51645.076% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -482063.291% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2479900.0% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -11812178.86% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -7273.25% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -73602.855% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -755905.365% |
| SQZ Biotechnologies Company | 27.47 Million USD | -10958.935% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -130513.017% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -320272.552% |
| Mesoblast Limited | 118.7 Million USD | -2459.385% |
| Marizyme, Inc. | 18.71 Million USD | -16130.805% |
| Genus plc | 233.1 Million USD | -1203.303% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -103572.278% |
| Pharming Group N.V. | 171.54 Million USD | -1670.964% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -341992.462% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -226011.654% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -404966.667% |
| ContraFect Corporation | 2.88 Million USD | -105349.497% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2242181.547% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -209950.48% |
| IMV Inc. | 28.88 Million USD | -10417.971% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -53590.535% |
| MultiCell Technologies, Inc. | 202.58 USD | -1499654357.498% |
| ONE Bio Corp. | 19.71 Million USD | -15309.57% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -5184.489% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -203144.554% |
| Q BioMed Inc. | 4.1 Million USD | -73817.617% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -9077.97% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -247221.431% |
| Biomind Labs Inc. | 735.54 Thousand USD | -412928.76% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -4391.236% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -100290.227% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -23274.634% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -844469.236% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2146623.385% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -134421.146% |
| GB Sciences, Inc. | 1.75 Million USD | -172581.63% |
| Alpha Cognition Inc. | 1.22 Million USD | -248840.487% |
| HST Global, Inc. | 98.31 Thousand USD | -3089841.924% |
| CSL Limited | 12.18 Billion USD | 75.064% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1221353.844% |
| Halberd Corporation | 150 Thousand USD | -2025233.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -304816.605% |
| Agentix Corp. | 50 Thousand USD | -6075900.0% |
| Resverlogix Corp. | 6.49 Million USD | -46703.266% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1188513.102% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | -15090.0% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -42853.225% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -112056.999% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -29711391.443% |
| Genscript Biotech Corporation | 417.73 Million USD | -627.249% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1514235.846% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -126603.49% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1324853.88% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2043571.882% |
| Kadimastem Ltd | 891.22 Thousand USD | -340778.745% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1214215.978% |
| LadRx Corporation | 33.6 Thousand USD | -9039952.372% |
| Cell Source, Inc. | 9.25 Million USD | -32728.43% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -401643.445% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -401643.445% |
| NovAccess Global Inc. | 2.19 Million USD | -137998.442% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -1330156.549% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1439881.04% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -60867.289% |
| Mobile Lads Corp. | 484.28 Thousand USD | -627217.855% |
| CytoDyn Inc. | 30.07 Million USD | -10001.077% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -38749.304% |
| SYBLEU INC | 477.5 Thousand USD | -636130.366% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -64056.686% |
| International Stem Cell Corporation | 4.17 Million USD | -72614.217% |
| Bioxytran, Inc. | 1.92 Million USD | -157718.182% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4867475.665% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -139200.289% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -36431.987% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -35287.303% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -195209.612% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1133482.09% |
| Neutra Corp. | 54.15 Thousand USD | -5609620.068% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -165910.929% |
| PureTech Health plc | 25.51 Million USD | -11808.122% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -248056.795% |
| IXICO plc | 472.02 Thousand USD | -643512.705% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -19498.736% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -4779.302% |
| CSL Limited | 12.18 Billion USD | 75.064% |
| Cellectis S.A. | 92.77 Million USD | -3174.536% |